ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,618.26
-0.29%
US Tech 100
18,902.40
-0.20%
Dow Jones
41,503.10
-0.25%
Brent Oil
72.43
-1.21%
Bitcoin
60,366.61
0.11%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Syndax Pharmaceuticals Inc (SNDX) Quote

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc (SNDX)

NASDAQ
18.00
-0.06
(-0.33%)
At close: September 18 4:00PM
Delayed by 15 minutes
18.00
0.00
( 0.00% )
After Hours: 4:30PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
18.00
Bid
18.00
Ask
18.80
Volume
1,961,592
17.34 Day's Range 18.22
11.215 52 Week Range 25.34
Market Cap
1.532B
Previous Close
18.06
Open
18.07
Last Trade
1
@
18.18
Last Trade Time
16:10:34
Financial Volume
$ 35,031,881
VWAP
17.8589
Average Volume (3m)
991,871
Shares Outstanding
85,096,358
Dividend Yield
-
PE Ratio
-7.32
Earnings Per Share (EPS)
-2.46
Revenue
-
Net Profit
-209.36M

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.syndax.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Syndax Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SNDX. The last closing price for Syndax Pharmaceuticals was $18.06. Over the last year, Syndax Pharmaceuticals shares have traded in a share price range of $ 11.215 to $ 25.34.

Syndax Pharmaceuticals currently has 85,096,358 shares outstanding. The market capitalization of Syndax Pharmaceuticals is $1.54 billion. Syndax Pharmaceuticals has a price to earnings ratio (PE ratio) of -7.32.

Ask ADVFN Intelligence (AI)

Syndax Pharmaceuticals (SNDX) Options Flow Summary

SNDX Options Flow

Overall Flow

Bullish

Net Premium

430k

Calls / Puts

350.00%

Buys / Sells

350.00%

OTM / ITM

200.00%

Sweeps Ratio

0.00%

SNDX Latest News

More News

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease PR...

17 minutes ago
PR Newswire (US)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Sept. 6, 2024 WALTHAM, Mass., Sept. 6, 2024 /PRNewswire/ -- Syndax...

September 06 2024
PR Newswire (US)

Incyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)

Niktimvo™ (Axatilimab-csfr) ist der erste zugelassene Anti-CSF-1R-Antikörper, der auf die Ursachen von Entzündung und Fibrose bei chronischer GvHD abzielt Daten der AGAVE-201-Studie, die die...

August 15 2024
Business Wire

Incyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)

Niktimvo™ (axatilimab-csfr) est le premier anticorps anti-CSF-1R autorisé à cibler les moteurs de l’inflammation et de la fibrose observés dans la GVHD chronique Les données clés de l’étude...

August 15 2024
Business Wire

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Niktimvo™ (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD Pivotal data from the AGAVE-201 study supporting...

August 14 2024
Business Wire

Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia PR Newswire WALTHAM, Mass...

August 12 2024
PR Newswire (US)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Aug. 5, 2024 WALTHAM, Mass., Aug. 5, 2024 /PRNewswire/ -- Syndax...

August 05 2024
PR Newswire (US)

Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update

Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update PR Newswire WALTHAM, Mass., Aug. 1, 2024 –  Axatilimab BLA in refractory chronic GVHD is under...

August 01 2024
PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 01 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 01 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.66-3.5369774919618.6619.3317.92137091718.31391486CS
4-2.51-12.237932715720.5121.5617.9293703619.22979626CS
12-1.71-8.6757990867619.7125.0717.9299187120.96777551CS
26-5.37-22.978177150223.3725.0717.92101281421.04837352CS
520.623.5673187571917.3825.3411.215135040018.75480762CS
156-1.18-6.1522419186719.1829.8611.21592494319.74170227CS
2609.16103.6199095028.8429.865.3576204919.18801616CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
XCURExicure Inc
$ 6.0395
(163.73%)
6.55M
VEROVenus Concept Inc
$ 1.07
(112.94%)
7.73M
ZEOZeo Energy Corporation
$ 1.70
(49.12%)
87.41k
TBIOTelesis Bio Inc
$ 1.74
(27.94%)
689.71k
RELIReliance Global Group Inc
$ 3.07
(18.08%)
74.59k
SMFLSmart for Life Inc
$ 0.5093
(-34.71%)
1.63M
PGNYProgyny Inc
$ 18.28
(-25.20%)
75.11k
CRMTAmericas Car Mart Inc
$ 44.00
(-11.93%)
5.81k
OMEXOdyssey Marine Exploration Inc
$ 1.25
(-10.71%)
3.88M
RNAZTransCode Therapeutics Inc
$ 0.3156
(-9.83%)
179.55k
VEROVenus Concept Inc
$ 1.07
(112.94%)
7.73M
XCURExicure Inc
$ 6.0395
(163.73%)
6.55M
NVDANVIDIA Corporation
$ 113.44
(0.06%)
5.26M
OMEXOdyssey Marine Exploration Inc
$ 1.25
(-10.71%)
3.85M
EJHE Home Household Service Holdings Ltd
$ 0.105
(-0.94%)
3.61M

SNDX Discussion

View Posts
dinogreeves dinogreeves 3 days ago
Have you looked at TIL on Friday.
👍️0
Monksdream Monksdream 3 days ago
SNDX a buy again
👍️0
dinogreeves dinogreeves 12 months ago
SNDX had the highest volume today for some reason, this is either going to tank hard on Monday or hit 30...50....60 dollars. Took my chances with 600 shares.
👍️0
dinogreeves dinogreeves 12 months ago
Possibly a huge run on Monday, very possible or they missed the trial. Huge 400 million in the coffers and monster institutional ownership.
👍️0
dealerschool2006 dealerschool2006 3 years ago
Nice rebound today for $SNDX, beat the street and conference call was successful!!!
👍️0
dealerschool2006 dealerschool2006 3 years ago
SNDX recovering from panic sale!!!
👍️0
dealerschool2006 dealerschool2006 3 years ago
Panic sale for SNDX on positive results...May options wide swings...
👍️0
DaytraderJohn DaytraderJohn 4 years ago
Its interesting how a company such as this can go on to have revenue loss of 50m+ per year. Yet still give higher ups 200k+ cash bonuses and large salaries.

They have no product revenue.

I expect shares to be diluted after earnings.

Read their 10k. I guess it's a gamble play incase one day they do get approval.
👍️0
BoilerRoom BoilerRoom 5 years ago
$SNDX looks like this run is going to continue. Let’s hit $15.00 this week folks
👍️0
ClayTrader ClayTrader 5 years ago
* * $SNDX Video Chart 01-31-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
BoilerRoom BoilerRoom 5 years ago
$SNDX next week is going to be fun
👍️0
BoilerRoom BoilerRoom 5 years ago
$SNDX Hope you guys went all in here...Have a great weekend see y’all on Monday
👍️0
BoilerRoom BoilerRoom 5 years ago
$SNDX holding this baby!
👍️0
BoilerRoom BoilerRoom 5 years ago
$SNDX keep climbing baby! Going be going up all next week
👍️0
BoilerRoom BoilerRoom 5 years ago
$SNDX looking awesome from my call at $8.00
👍️0
BoilerRoom BoilerRoom 5 years ago
$SNDX got us a runner folks!!!
👍️0
BoilerRoom BoilerRoom 5 years ago
$SNDX Chomp Chomp Chomp!
👍️0
BoilerRoom BoilerRoom 5 years ago
$SNDX Weeeeeeeeeee
👍️0
BoilerRoom BoilerRoom 5 years ago
Going to run folks.
👍️0
BoilerRoom BoilerRoom 5 years ago
$SNDX in at $8.00
👍️0
TheFinalCD TheFinalCD 5 years ago
News News Alert: Syndax Announces $35.0 Million Offering of Common Stock...
👍️0
whytestocks whytestocks 5 years ago
News: $SNDX Syndax Announces $26.2 Million Offering of Common Stock and Warrants

WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...

Find out more https://marketwirenews.com/news-releases/syndax-announces-26-2-million-offering-of-common-stock-and-warrants-7897910.html
👍️0
DewDiligence DewDiligence 6 years ago
SNDX 3Q18 results—cash=$89.6M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical-and-business-update-300744153.html
👍️0
Spartak Spartak 6 years ago
Well, the company is done. What a disaster.
👍️0
DewDiligence DewDiligence 6 years ago
SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

The trial continues to test for statsig OS every six months until Nov 2019.
👍️0
DewDiligence DewDiligence 6 years ago
SNDX -20% on no news—sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.
👍️0
DewDiligence DewDiligence 6 years ago
SNDX upgrades BoD:

https://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html
👍️0
DewDiligence DewDiligence 6 years ago
#msg-143766395
👍️0
DewDiligence DewDiligence 6 years ago
SNDX phase-3 PFS data now expected in 4Q18 (rather than 3Q18); I essentially called this back in May (#msg-140923103, bottom):

https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer-300717717.html
👍️0
DewDiligence DewDiligence 6 years ago
#msg-143642544
👍️0
DewDiligence DewDiligence 6 years ago
SNDX 2Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-152734163.html
👍️0
DewDiligence DewDiligence 6 years ago
SNDX 2Q18 items—6/30/18 cash=$98.4M…

PR:
http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-second-quarter-2018-financial

CC slides:
http://ir.syndax.com/static-files/18eaf63a-6c93-45cd-8272-60479300c153
👍️0
Spartak Spartak 6 years ago
When does pounding stop? Someone hummers it pretty badly.
👍️0
fsantes fsantes 6 years ago
Ill keep a look out for some then!... I’ve been looking as well. Thank you!
👍️0
DewDiligence DewDiligence 6 years ago
No. I generally post anything that's material.
👍️0
fsantes fsantes 6 years ago
Have you heard any new news on SNDX?
👍️0
fsantes fsantes 6 years ago
I really appreciate it. Bought some shares as one advisor mentioned it to me but keeping track of what’s going on on it
👍️0
DewDiligence DewDiligence 6 years ago
SNDX requested that the SEC keep this document in redacted form:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-ex101_169.htm

This was filed as an exhibit to the most recent 10-Q.
👍️0
fsantes fsantes 6 years ago
Do you know what’s the news that came out about? When I look it’s blank..
👍️0
DewDiligence DewDiligence 6 years ago
SNDX, NKTR ink clinical-trial collaboration for Entinostat + NK-214 in second-lime melanoma:

https://www.prnewswire.com/news-releases/syndax-and-nektar-therapeutics-announce-immuno-oncology-clinical-trial-collaboration-300656793.html

NKTR is furnishing free drug for the phase-1/2 clinical trial, but no cash.
👍️0
DewDiligence DewDiligence 6 years ago
SNDX ENCORE-601 update…

PR:
https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-300650233.html

CC slides:
http://ir.syndax.com/static-files/7c0c8627-0b81-43d6-9210-6cb02684db5f
👍️0
tika1 tika1 6 years ago
After failure of two high profile IO combination, I think SNDX will go nowhere for its own IO combo.

All eyes on Etinostat + exemestane only. Still chance of double, if that turns out good.
👍️0
DewDiligence DewDiligence 6 years ago
Transcript of SNDX 1Q18 CC:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-235620976.html
👍️0
DewDiligence DewDiligence 6 years ago
SNDX new investor slide set:

http://ir.syndax.com/static-files/da19e99b-2bd2-4456-91fe-0e67b97fc0d0
👍️0
DewDiligence DewDiligence 6 years ago
The 1Q18 10-Q has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-10q_20180331.htm
👍️0
DewDiligence DewDiligence 6 years ago
SNDX 1Q18 results—cash=$113M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-clinical-and-business-update-300644832.html
👍️0
DewDiligence DewDiligence 6 years ago
SNDX ASCO lineup:

https://finance.yahoo.com/news/syndax-pharmaceuticals-announces-presentations-2018-200500073.html
👍️0
DewDiligence DewDiligence 6 years ago
Yes—please see my reply in #msg-140012720.
👍️0
tika1 tika1 6 years ago
Dew,
Is there any hope for success of this trial after high profile INCY failure? What is your take on SNDX current weakness?


Oral Presentations:

Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Presenter: Anthony W. Tolcher, M.D.
Category: Clinical Trials
Session: Biomarkers in Immuno-oncology
Abstract Number: CT179
Location: N Hall C - McCormick Place North (Level 1)
Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
👍️0
DewDiligence DewDiligence 6 years ago
SNDX presentation lineup at AACR:

https://finance.yahoo.com/news/syndax-present-2018-american-association-110000742.html
👍️0

Your Recent History

NASDAQ
SNDX
Syndax Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved